| JUL - 2 2002
Laserscope
Lyra™ Surgical Laser System & Accessories
510(k) Premarket Notification
o
510(k) Summary K 0200 3 (
This 510(k) Summary of Safety & Effectiveness for the Laserscope’s Lyra Surgical Laser
System & Accessories is submitted in accordance with the requirements of SMDA 1990
and CFR 807.92 and CFR 807.93 follows Office of Device Evaluation guidance
concerning the organization and content of a 510(k) summary.
A. Trade Name
Lyra™ Surgical Laser System and Accessories (Nd:YAG configuration)
B. Common Name
Laser Instrument, Surgical, Powered
C. Establishment Registration Number
2937094
D. Manufacturer's Identification
Laserscope
3070 Orchard Drive
San Jose, CA 95134-2011
(408) 943-0636
(503) 961-1688 FAX
Official Correspondent
Paul Hardiman
Manager, Regulatory Affairs/Clinical Affairs
E. Device Classification
The Lyra™ Series Surgical Laser System has been specifically classified as a
Class II medical device by the OB/GYN, General Plastic Surgery, and ENT
Device Advisory Panels.
F, Performance Standards
The Lyra™ Series Surgical Laser System conforms with federal regulations and
the performance standards 21 CFR 1040.10 and 1040.11 for medical laser
systems.
G. Device Description
The Lyra™ Series Surgical Laser Systems are Nd:YAG lasers producing laser
emission @ 1064nm. The Laserscope Lyra Surgical Laser System consists of
four major subsystems:
000001

os The Optical and Laser Resonator system; The Cooling system; The Electronics and
. Electrical system; The Operator interface.

G. Substantial Equivalence
In the opinion of Laserscope, the Laserscope Lyra™ Surgical Laser System &
Accessories is substantially equivalent in technology and intended use to the
Lyra™ Surgical Laser System FDA cleared under 510(k) K9990903, the
CoolTouch Nd:YAG Laser System FDA cleared under 510(k) K003715, and the
SLS NLite System FDA cleared under 510(k) K000811.

H. Indications For Use:
The Laserscope Lyra™ Laser Systems & Accessories are indicated for use in
the Dermatological applications for the treatment of facial wrinkles.

” L Nonclinical Performance Data:

None.

J. Clinical Performance Data:
Clinical studies produced results that indicate the Laserscope Lyra™ Laser
Systems & Accessories is safe and effective for the treatment of facial wrinkles.

0eedce2

net,
é Le DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
“ae a
. - Food and Drug Administration
: 9200 Corporate Boulevard
: : Rockville MD 20850
JUL = 2 2002

Laserscope .
Paul ‘Hardiman
Manager, Regulatory Affairs/Clinical Affairs
3070 Orchard Drive
San Jose, California 95134-2011
Re: K020021

Trade Name: Lyra G™ Series Laser System and Accessories (Nd: YAG configuration)

. Regulation Number: 878.4810

Regulation Name: Laser surgical instrument, powered

Regulatory Class: II

Product Code: GEX

Dated: April 11, 2002

Received: April 12, 2002
Dear Mr. Hardiman:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and we have determined the device is substantially equivalent (for the
indications for use stated in the enclosure) to devices marketed in interstate commerce prior to
May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have
been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act
(Act) that do not require approval of a premarket approval application (PMA). You may,
therefore, market the device, subject to the general controls provisions of the Act. The general
controls provisions of the Act include requirements for annual registration, listing of devices,
good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class I (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA bas made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Paul Hardiman .. a Lo :
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally

: marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market. os
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and
additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of
Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of
your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the
regulation entitled, "Misbranding by reference to premarket notification” (21CFR Part 807.97).
Other general information on your responsibilities under the Act may be obtained from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number

, (800) 638-2041 or (301) 443-6597 or at its Internet address
http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
fre ia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health .
Enclosure

, INDICATIONS FOR USE STATEMENT ~——
. . Page 1 of 1
510(k) Number: . , Ko2a00a \
Device Name: LASERSCOPE LYRA™ SERIES SURGICAL
. LASER SYSTEM & Accessories
Indications for Use: The Laserscope Lyra™ Laser Systems & Accessories are
indicated for use in the Dermatological applications for the
treatment of facial wrinkles.
(PLEASE DO NOT WRITE BELOW THIS LINE ~ CONTINUE ON ANOTHER PAGE)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use-——SH=- or Over -The-Counter-Use
(per 21 CFR 801.109)
Qivision Po '
Division of General, Restorative
and Neurological Devices
7
510(k) Number__Koucor 000003

